Toripalimab in Combination With Axitinib in Patients With Localized Mucosal Melanoma
This study is one monocentric, single-arm, open, phase Ⅱ clinical study to evaluate the
safety and efficacy of Toripalimab monoclonal injection (Tuo Yi) combined with axitinib
tablet (Inlyta®) as neoadjuvant therapy for localized mucosal melanoma.
Primary objective: To evaluate pathological response (pCR+pPR) rate of Toripalimab combined
with axitinib as neoadjuvant therapy for localized mucosal melanoma.
The subjects will receive Toripalimab and Axitinib combined therapy after enrollment, and
receive operation 2 weeks after the last dose of Axitinib. Toripalimab will be given for a
total of 4 cycles (8 weeks), whereas Axitinib...